Literature DB >> 27626246

Morphologic predictors of in hospital mortality in acute type III aortic dissection.

N Fatic1, N Ilić2, D Markovic2, A Nikolic1, I Končar2, R Lazovic1, I Banzic2, G Vuktsevich1, B Pajovic1, D Kostic2.   

Abstract

INTRODUCTION: In-hospital mortality of acute aortic type III dissection ranged about 12%. Complicated dissections represent about 18% of all cases, and require open surgery or TEVAR. More morphological predictors of in hospital mortality are needed to differentiate patients who should be selected for immediate, surgical or endovascular intervention.
METHODS: From January 2009 to December 2014, 74 patients with acute aortic type III dissection were enrolled at Clinic of Vascular and Endovascular Surgery in Belgrade Serbia and retrospectively analyzed. Every MSCT was observed in regard to morphologic characteristics of dissection.
RESULTS: By analyzing morphologic parameters in patients between survival and non-survival group only localization of intimal tear showed statistical significance (p=0,020). The size of the intimal tear didn't reach statistical significance with the tendency of doing so in a larger sample of patients (p=0,063) with the cut-off value of 9.55mm. The shape of the true lumen was on the border of statistical significance (p=0,053).
CONCLUSION: Inner curvature intimal tear localization, huge intimal tear as well as elliptic shape of the true lumen together should raise awareness to a subgroup at risk for in hospital mortality. More liberal endovascular treatment in this subgroup of patients is advocated.

Entities:  

Mesh:

Year:  2016        PMID: 27626246

Source DB:  PubMed          Journal:  Angiol Sosud Khir        ISSN: 1027-6661


  1 in total

1.  Application of thoracic endovascular aortic repair (TEVAR) in treating dwarfism with Stanford B aortic dissection: A case report.

Authors:  Jian Qiu; Wenwu Cai; Chang Shu; Ming Li; Qinggen Xiong; Quanming Li; Xin Li
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.